Marker Therapeutics

MRKR · NASDAQ

$1.16−$0.04 (−3.33%)TodayMarket closed ·
Prev close $1.20

About MRKR

The company is headquartered in Houston, Texas and currently employs 5 full-time employees. The company went IPO on 2016-11-08.

Employees
5
Headquarters
Houston, Texas
Listed
Nov 8, 2016
Sector
Health Care
Industry
Biotechnology

MRKR key statistics

Market cap
19.34M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
161.95K
Volume
209.23K
Open price
$1.19
High today
$1.24
Low today
$1.11
52 Week high
$2.46
52 Week low
$0.84

Marker Therapeutics (MRKR) at a glance

As of Oct 20, 2026, Marker Therapeutics (MRKR) shares are priced at $1.16, giving the company a market cap of 19.34M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.11 and $1.24. The current price is 4.5% above the day's low and 6.5% below its high.

Volume so far is 209.23K shares, above the average of 161.95K shares a day.

Over the past year Marker Therapeutics has ranged from $0.84 to $2.46, and now sits 20% of the way up that range.

Marker Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.09 per share against an estimate of -$0.221.

The average analyst price target is $8.02, 591.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $8.02
Low
$5.66
Now
$1.16
High
$10.50

MRKR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 42.3% on average.

  1. Q3 FY24: reported -$0.26 per share against an estimate of -$0.3978
  2. Q4 FY24: reported -$0.42 per share against an estimate of -$0.2239
  3. Q1 FY25: reported -$0.36 per share against an estimate of -$0.5003
  4. Q2 FY25: reported -$0.29 per share against an estimate of -$0.4182
  5. Q3 FY25: reported -$0.12 per share against an estimate of -$0.459
  6. Q4 FY25: reported -$0.09 per share against an estimate of -$0.2006
  7. Q1 FY26: reported -$0.16 per share against an estimate of -$0.187
  8. Q2 FY26: reported -$0.09 per share against an estimate of -$0.221

MRKR news

  • Press releaseGlobe Newswire

    Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

  • Press releaseGlobe Newswire

    Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

  • Press releaseGlobe Newswire

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

  • Press releaseGlobe Newswire

    Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

  • Press releaseGlobe Newswire

    Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell Technology

  • Press releaseGlobe Newswire

    Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

  • Press releaseGlobe Newswire

    Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Similar companies

Companies in the same industry as Marker Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.